Introduction
Sl eep plays an important role in human health, with implications for memory 1 and cognitive function, 2 depression and anxiety, 3 abuse of alcohol 4 and drugs, 5 cardiovascular outcomes, 6 and more. A meta-analysis showed that people who neither oversleep nor undersleep have the lowest mortality risk. 7 Laboratory and epidemiologic evidence suggests that sleep loss and poor sleep quality may promote the development of obesity and diabetes and exacerbate these conditions. 8, 9 In the face of the many other challenges faced by people with type 1 diabetes mellitus (T1DM), sleep health is not often considered in the course of an individual's diabetes management and care. The research community has only just begun to explore sleep characteristics in adults with T1DM. Controlled studies with small sample sizes showed that adults with T1DM have altered neuroendocrine sleep architecture 10 and that insulin sensitivity is affected by sleep deprivation. 11 A larger subjective study reported that adults with long-standing T1DM have disturbed sleep quality and a higher risk for obstructive sleep apnea, while finding no significant association between individual sleep characteristics and hemoglobin A1c (HbA1c) values. 12 Many individuals in this study reported frequent sleep disturbance from hypoglycemia.
Hypoglycemia during sleep represents a great health risk to people with T1DM. 13 As reviewed by Jauch-Chara and Schultes, 14 nocturnal hypoglycemia is common but often undetected. In fact, people with T1DM frequently fail to wake up during nocturnal hypoglycemia, which in some cases leads to coma and even death. Frequently asymptomatic, nocturnal hypoglycemia can impair wellbeing on the subsequent day and negatively impact awareness of and response to subsequent hypoglycemic episodes.
To date, only a few studies have explored T1DM nocturnal glycemia during sleep. 10, [15] [16] [17] As most sleep research is conducted in a controlled laboratory setting, the expense of collecting objective sleep data from patients with diabetes has constrained large-scale studies in this domain, thus limiting the application of sleep health knowledge in diabetes care. The advent of ubiquitous body-worn sensing technologies has contributed to the availability of affordable, user-friendly wireless sleep monitors (WSMs) that can be employed to collect objective sleep data comparable to polysomnography, the gold standard of sleep recording. [18] [19] [20] These new WSM devices may provide a means to expand our knowledge about real-world sleep characteristics in the broader T1DM population.
In this study, we analyzed nocturnal glycemia and sleep stages in patients with T1DM in an unsupervised real-world setting. Our results reveal new knowledge about the relationship between glycemia and sleep stages and provide evidence for the feasibility of collecting objective sleep data outside the controlled laboratory environment.
Methods
Data were collected as part of the Diabetes Management Integrated Technology Research Initiative (DMITRI) pilot study, a community research partnership between the University of California, San Diego, and Insulindependence. 21 The DMITRI pilot study was exploratory in nature and not powered to evaluate specific outcomes. The study included Abstract cont.
Conclusions:
Increased time in deep sleep was associated with lower HbA1c, and less hypoglycemia occurred in deep sleep in T1DM, though this must be further evaluated in larger subsequent studies. Furthermore, the consumergrade WSM device was useful for objectively studying sleep in a real-world setting.
17 subjects with T1DM: 10 males and 7 females; ages 19-61 years; T1DM duration 14.9 ± 11.0 years; HbA1c 7.3% ± 1.3% (mean ± standard deviation). Trait daytime sleepiness was assessed by the Epworth sleepiness scale (ESS), a validated questionnaire to assess daytime sleepiness. 22 Subjects were free to roam the university campus and surrounding area over a study period of four days and slept for four nights in unsupervised dormitories with shared bedrooms.
The study employed continuous glucose monitors (CGMs; SEVEN PLUS, Dexcom Inc., San Diego, CA), worn by each subject at all times, and consumer-grade WSMs (Bedside Sleep Manager, Zeo Inc., Newton, MA), worn from bedtime until morning waking. The WSM device consists of a lightweight sensor headband that continuously records electroencephalogram (EEG) data that are transmitted wirelessly to a bedside receiver unit, where an algorithm processes the data and provides a sleep stage value for each 30 s interval. These time-stamped values are stored on a memory card in the receiver for subsequent retrieval and analysis. 20 Sleep is a highly structured set of processes separated into four stages [N1, N2, N3, and rapid eye movement (REM) sleep], 23 each demonstrating stereotypic electrical and neuromodulatory activity in the brain. 24 The WSM algorithm employed in the present study categorizes the EEG data into one of three sleep stages, namely, REM, light (i.e., N1 and N2), and deep (i.e., N3).
Following the study period, data were retrieved from each device for preprocessing and analysis (R, Matlab, Excel). The WSM data were collected for a total of 52 subject-nights. Because the WSM sampled data at a higher rate than the CGM (two samples per minute versus one sample per 5 min), WSM data were binned into 5 min intervals synchronized with the CGM data, and the mode sleep stage for each interval was calculated to generate a comparable epoch length for subsequent analysis. Sleep start and end times were determined based on WSM data, as the devices automatically start and stop collecting data when the headband is attached to or removed from the head, and times of sleep onset and waking are evident in the data. A subset of subjects (n = 10) wore an additional monitoring device (Actiwatch-64, Philips-Respironics, Andover, MA) that was used only to determine sleep start and end times for nocturnal glycemia analyses (as in Tables 1 and 2) in the absence of reliable WSM data (user error or device malfunction). Subject-nights without WSM data were excluded from any analyses of sleep characteristics (as in Table 3 and Figure 1 ). For analysis of glycemia during sleep stages, WSM data from each subject-night were normalized to correct for differences in duration of each sleep stage [specifically, for each subject-night, duration in each sleep stage was converted to percentage of total sleep time (TST) to enable comparison of multiple subject-nights regardless of TST]. Differences in glycemic range per sleep stage were assessed with Wilcoxon rank-sum test.
Results

Characterization of Nocturnal Glycemia
We calculated the nocturnal time spent in different ranges of glycemia, designated as hypoglycemia (<50 mg/dl), low (50-69 mg/dl), euglycemia (70-120 mg/dl), high (121-250 mg/dl), and hyperglycemia (>250 mg/dl). Calculations were performed on 43 subject-nights with ≥48 CGM data points (i.e., ≥4 h). As shown in Table 1 , T1DM nocturnal dysglycemia observed here differs from the tightly controlled nocturnal glycemia measured in healthy adults in other studies. 10, 25 Substantial variability was observed between individuals' nocturnal glycemia. Marked intraindividual variability was observed from night to night, in agreement with previous findings. 26 Nocturnal hypoglycemia (<50 mg/dl) was observed for seven subjects.
We further characterized nocturnal glycemia using different measures of glycemic variability (GV). [27] [28] [29] Nocturnal CGM data were analyzed with previously developed software to compute GV for each subject-night. 29 As shown in Table 2 , we observed substantially increased nocturnal GV in the study cohort as compared with reference values in healthy individuals. 29 These findings are in agreement with other observations of increased nocturnal GV in professional cyclists with T1DM as compared with their nondiabetic counterparts. 30 Substantial variability was observed between individuals, and marked intraindividual variability was observed from night to night.
Characterization of Sleep
Subjects in this study had higher levels of trait daytime sleepiness (8.4 ± 3.9, mean ± standard deviation) than previously reported for T1DM (5.9 ± 4.0; p < .02), 12 with five subjects scoring ≥10 on the ESS, usually interpreted as hypersomnolence (excessive sleepiness). From 48 subject-nights with ≥4 h of WSM data, we calculated the subjects' average TST to be slightly less than 6 h ( Table 3) , less than the 7.2 h previously self-reported for people with T1DM 12 and less than the United States national average of approximately 7 h in adults over the age of 19 years. 31 To characterize the time spent in different sleep stages in T1DM, we calculated the percentage of time in REM, light, and deep sleep for each subject-night. Notably, we observed a negative correlation between time spent in deep sleep and HbA1c (R 2 = 0.42; F = 9.37; p < .01), indicating that increased time in deep sleep is associated with lower HbA1c. This is in agreement with previous findings suggesting a role for deep sleep in glycemic control. [32] [33] [34] No significant relationships were observed between HbA1c or ESS and any other sleep traits in Table 3 .
Glycemia during Different Sleep Stages
We assessed glycemia as it occurs within each sleep stage, calculating the time spent in each glycemic range during REM, light, and deep sleep for 39 subject-nights with ≥4 h of WSM data and corresponding CGM data (missing CGM data ≤15 min were linearly interpolated). As shown in Figure 1 , while glycemia appears to be similar between sleep stages, we observed significantly less time spent in hypoglycemia during deep sleep compared with light sleep (p = .02, Wilcoxon rank-sum test). This trend is intriguing in light of our observation that increased time in deep sleep is related to lower HbA1c, as it suggests that decreased HbA1c is not due simply to hypoglycemia in deep sleep. The apparent difference in hypoglycemia between deep and REM sleep is not statistically significant. With respect to the other glycemic ranges, most (38-48%) REM, light, and deep sleep was characterized by euglycemia and high glycemia, and much less (5.5-7.4%) of each sleep stage was spent in low glycemia and hyperglycemia (Figure 1) , with no significant differences in glycemic range between sleep stages.
Discussion
We report decreased time spent in hypoglycemia during deep sleep relative to light sleep in T1DM and an association between increased deep sleep and lower HbA1c. These results suggest associations between glycemia and sleep stage that should be considered in diabetes care to reduce the risk of nocturnal hypoglycemia through improved sleep health and continuous sleep monitoring. Prior studies have demonstrated a role for slow wave sleep (SWS; i.e., deep sleep) in glucose maintenance and insulin sensitivity. 33, 34 Diabetes patients spend less time in SWS compared with N1, N2 (light sleep) 10, 35 and REM. 36 Compared with age-matched controls, children with T1DM spent more time in light sleep than SWS, and more time in light sleep was associated with higher average daily glucose values, more hyperglycemia, and higher HbA1c levels. 32 Behaviorally, increased time in light sleep was associated with parental reports of emotional and behavioral difficulties, reduced diabetes quality of life, lower grades, sleep-wake behavior problems, depressive mood, daytime poor sleep quality, sleepiness, and worse math performance, while increased deep sleep was associated with better outcomes. 32 The current results suggest that the beneficial effect of deep sleep may be due to decreased nocturnal hypoglycemia. Taken together, understanding of a causal relationship between sleep stages and blood glucose dynamics will be an important direction for future studies.
The data analyzed in this study were collected from subjects in real-world conditions, yet not in the familiar environment of their homes (or in their normal time zones, in some cases), which may impact sleep quality. It is also possible that sleep quality and traits could be affected by sleeping in shared dormitory rooms or changed by the absence of a normal sleep companion, such as a spouse or pet. The time spent in REM and light sleep by our subjects differs from previous findings. 10 The basis for the observed differences remains unclear but could arise from the different sleep monitoring technology employed or from the study sleep environment (clinical sleep laboratory versus realworld dormitory). Further, the experience of wearing a WSM, however unobtrusive, may require some acclimation time greater than the short study period evaluated here. Subsequent at-home observational studies, conducted over longer periods of time, may shed additional light on the relationship between typical sleep and nocturnal glycemia in the individual with T1DM. Collection of data from larger cohorts will also permit more fine-tuned analyses on the sleep quality effects of age, duration of diabetes, and other clinical characteristics, as the subjects in this exploratory study were diverse in these respects.
Research has explored the capacity of algorithmically processed EEG data to identify and signal the onset of hypoglycemia, including during sleep, with applications in patient-alarm systems. [37] [38] [39] [40] These strategies currently employ technologies more commonly associated with the clinical environment and have not, to our knowledge, been adapted to the EEG sensors found in consumer-grade devices such as the WSM used in the present study. It is quite possible, however, that improvements in EEG data collection and processing will enable consumer-grade WSM-based hypoglycemia prediction, of particular value during sleep when T1DM patients' ability to respond is compromised. 15 Further, more macro-level evaluations of sleep quality and duration may inform changes to daily insulin regimens, as partial sleep restriction has been shown to decrease insulin sensitivity in people with T1DM. 11 The use of bodyworn sensor data in the automated altering of insulin delivery has precedent in insulin pump systems with the low glucose suspend feature, which has been shown to decrease nocturnal hypoglycemia. 41 Perhaps such features can be even more effective in the context of sleep health data.
While a Food and Drug Administration-approved clinical decision-support process (open or closed loop) would likely require more sophisticated, validated sleep measurements than are presently available in consumer-grade sleepmonitoring technology, user-friendly devices such as the WSM employed here are being joined by a proliferation of smartphone applications that also purport to monitor sleep health. 42, 43 Self-monitoring trends in the population, such as "citizen science" and the quantified self, suggest that the popularity of these devices and applications will continue to grow in the foreseeable future. 44, 45 Further, data collected by and for the individual with diabetes lend themselves to evaluation by the increasingly discussed "n-of-1" paradigm for personalized health. [46] [47] [48] Regardless of the means by which sleep health is assessed in T1DM individuals and the population, one might envision that the availability of affordable real-world sleep monitoring technologies will offer insight and improvements for personal sleep management akin to the improved diabetes control imparted by use of CGM and insulin pumps. Digital systems that integrate and display data from these devices in meaningful ways are likely to be adopted into diabetes self-management and forward-looking clinical practice.
